Adjuvant effects of aluminium hydroxide-adsorbed allergens and allergoids - differences in vivo and in vitro

Clinical and Experimental Immunology

Volumn 176, Issue 3, 2014, Pages 310-319

  Heydenreich, B ^a   Bellinghausen, I ^a   Lund, L ^b   Henmar, H ^b   Lund, G ^b   Adler Wurtzen P ^b   Saloga, J ^a  

^a UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^b ALK ABELLÓ   (Denmark)

Author keywords

Allergen; Allergoid; Aluminium hydroxide; Dendritic cells; Th1 Th2

Indexed keywords

ALLERGEN; ALUMINUM HYDROXIDE; FORMALDEHYDE; GAMMA INTERFERON; GLUTARALDEHYDE; HISTAMINE; IMMUNOGLOBULIN G; IMMUNOLOGICAL ADJUVANT; INTERLEUKIN 10; INTERLEUKIN 13; INTERLEUKIN 4; LEUKOTRIENE;

ADSORPTION; ALLERGENICITY; ANIMAL EXPERIMENT; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ARTICLE; BASOPHIL; BETULA VERRUCOSA; BIRCH; CD4+ T LYMPHOCYTE; CELL PROLIFERATION; COCULTURE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DENDRITIC CELL; FEMALE; HISTAMINE RELEASE; HUMAN; HUMAN CELL; IMMUNOGENICITY; IN VITRO STUDY; IN VIVO STUDY; LEUKOCYTE ACTIVATION; MONOCYTE; MOUSE; NONHUMAN; PHLEUM PRATENSE; PRIORITY JOURNAL;

ALLERGEN; ALLERGOID; ALUMINIUM HYDROXIDE; DENDRITIC CELLS; TH1/TH2;

ADJUVANTS, IMMUNOLOGIC; ALLERGENS; ALUM COMPOUNDS; ALUMINUM HYDROXIDE; ANIMALS; APOPTOSIS; BASOPHILS; CYTOKINES; DENDRITIC CELLS; FEMALE; HISTAMINE RELEASE; HUMANS; IMMUNOGLOBULIN G; LEUKOTRIENES; LYMPHOCYTE ACTIVATION; MICE; PLANT EXTRACTS; T-LYMPHOCYTE SUBSETS;

EID: 84899087720     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/cei.12294     Document Type: Article

References (34)

1. Ricci M, Rossi O, Bertoni M, Matucci A. The importance of Th2-like cells in the pathogenesis of airway allergic inflammation. Clin Exp Allergy 1993; 23:360-369.
2. Calderon MA, Casale TB, Togias A, Bousquet J, Durham SR, Demoly P. Allergen-specific immunotherapy for respiratory allergies: from meta-analysis to registration and beyond. J Allergy Clin Immunol 2011; 127:30-38.
3. Jacobsen L, Niggemann B, Dreborg S etal. Specific immunotherapy has long-term preventive effect of seasonal and perennial asthma: 10-year follow-up on the PAT study. Allergy 2007; 62:943-948.
4. Bellinghausen I, Metz G, Enk AH, Christmann S, Knop J, Saloga J. Insect venom immunotherapy induces interleukin-10 production and a Th2-to-Th1 shift, and changes surface marker expression in venom-allergic subjects. Eur J Immunol 1997; 27:1131-1139.
5. Jutel M, Akdis M, Budak F etal. IL-10 and TGF-beta cooperate in the regulatory T cell response to mucosal allergens in normal immunity and specific immunotherapy. Eur J Immunol 2003; 33:1205-1214.
6. Bellinghausen I, König B, Böttcher I, Knop J, Saloga J. Inhibition of human allergic T-helper type 2 immune responses by induced regulatory T cells requires the combination of interleukin-10-treated dendritic cells and transforming growth factor-beta for their induction. Clin Exp Allergy 2006; 36:1546-1555.
7. Jutel M, Akdis CA. Immunological mechanisms of allergen-specific immunotherapy. Allergy 2011; 66:725-732.
8. Marsh DG, Lichtenstein LM, Campbell DH. Studies on 'allergoids' prepared from naturally occurring allergens. I. Assay of allergenicity and antigenicity of formalinized rye group I component. Immunology 1970; 18:705-722.
9. Yang X, Gieni RS, Mosmann TR, HayGlass KT. Chemically modified antigen preferentially elicits induction of Th1-like cytokine synthesis patterns in vivo. J Exp Med 1993; 178:349-353.
10. von Baehr V, Hermes A, von Baehr R etal. Allergoid-specific T-cell reaction as a measure of the immunological response to specific immunotherapy (SIT) with a Th1-adjuvanted allergy vaccine. J Invest Allergol Clin Immunol 2005; 15:234-241.
11. Ibarrola I, Sanz ML, Gamboa PM etal. Biological characterization of glutaraldehyde-modified Parietaria judaica pollen extracts. Clin Exp Allergy 2004; 34:303-309.
12. Casanovas M, Fernandez-Caldas E, Alamar R, Basomba A. Comparative study of tolerance between unmodified and high doses of chemically modified allergen vaccines of Dermatophagoides pteronyssinus. Int Arch Allergy Immunol 2005; 137:211-218.
13. HogenEsch H. Mechanism of immunopotentiation and safety of aluminum adjuvants. Front Immunol 2013; 3:406.
14. Francis JN, Durham SR. Adjuvants for allergen immunotherapy: experimental results and clinical perspectives. Curr Opin Allergy Clin Immunol 2004; 4:543-548.
15. Glenny AT, Buttle AH, Stevens MF. Rate of disappearance of diphtheria toxoid injected into rabbits and guinea-pigs: toxoid precipitated with alum. J Pathol Bacteriol 1931; 34:267-275.
16. Harrison WT. Some observations on the use of alum precipitated diphtheria toxoid. Am J Public Health Nations Health 1935; 25:298-300.
17. Eisenbarth SC, Colegio OR, O'Connor W, Sutterwala FS, Flavell RA. Crucial role for the Nalp3 inflammasome in the immunostimulatory properties of aluminium adjuvants. Nature 2008; 453:1122-1126.
18. Li H, Willingham SB, Ting JP, Re F. Cutting edge: inflammasome activation by alum and alum's adjuvant effect are mediated by NLRP3. J Immunol 2008; 181:17-21.
19. Franchi L, Nunez G. The Nlrp3 inflammasome is critical for aluminium hydroxide-mediated IL-1beta secretion but dispensable for adjuvant activity. Eur J Immunol 2008; 38:2085-2089.
20. McKee AS, Munks MW, MacLeod MK etal. Alum induces innate immune responses through macrophage and mast cell sensors, but these sensors are not required for alum to act as an adjuvant for specific immunity. J Immunol 2009; 183:4403-4414.
21. Kuroda E, Ishii KJ, Uematsu S etal. Silica crystals and aluminum salts regulate the production of prostaglandin in macrophages via NALP3 inflammasome-independent mechanisms. Immunity 2011; 34:514-526.
22. Heydenreich B, Bellinghausen I, Lorenz S etal. Reduced in vitro T-cell responses induced by glutaraldehyde-modified allergen extracts are caused mainly by retarded internalization of dendritic cells. Immunology 2012; 136:208-217.
23. Rask C, Lund L, Lund G etal. An alternative allergen:adjuvant formulation potentiates the immunogenicity and reduces allergenicity of a novel subcutaneous immunotherapy product for treatment of grass-pollen allergy. Clin Exp Allergy 2012; 42:1356-1368.
24. Wurtzen PA, Lund L, Lund G, Holm J, Millner A, Henmar H. Chemical modification of birch allergen extract leads to a reduction in allergenicity as well as immunogenicity. Int Arch Allergy Immunol 2007; 144:287-295.
25. Rueff F, Wolf H, Schnitker J, Ring J, Przybilla B. Specific immunotherapy in honeybee venom allergy: a comparative study using aqueous and aluminium hydroxide adsorbed preparations. Allergy 2004; 59:589-595.
26. Rimaniol AC, Gras G, Verdier F etal. Aluminum hydroxide adjuvant induces macrophage differentiation towards a specialized antigen-presenting cell type. Vaccine 2004; 22:3127-3135.
27. Sokolovska A, Hem SL, HogenEsch H. Activation of dendritic cells and induction of CD4(+) T cell differentiation by aluminum-containing adjuvants. Vaccine 2007; 25:4575-4585.
28. Ulanova M, Tarkowski A, Hahn-Zoric M, Hanson LA. The common vaccine adjuvant aluminum hydroxide up-regulates accessory properties of human monocytes via an interleukin-4-dependent mechanism. Infect Immun 2001; 69:1151-1159.
29. Romani N, Reider D, Heuer M etal. Generation of mature dendritic cells from human blood. An improved method with special regard to clinical applicability. J Immunol Methods 1996; 196:137-151.
30. de Vries JE. The role of IL-13 and its receptor in allergy and inflammatory responses. J Allergy Clin Immunol 1998; 102:165-169.
31. Comoy EE, Capron A, Thyphronitis G. In vivo induction of type 1 and 2 immune responses against protein antigens. Int Immunol 1997; 9:523-531.
32. Wilcock LK, Francis JN, Durham SR. Aluminium hydroxide down-regulates T helper 2 responses by allergen-stimulated human peripheral blood mononuclear cells. Clin Exp Allergy 2004; 34:1373-1378.
33. Li H, Nookala S, Re F. Aluminum hydroxide adjuvants activate caspase-1 and induce IL-1beta and IL-18 release. J Immunol 2007; 178:5271-5276.
34. Besnard AG, Guillou N, Tschopp J etal. NLRP3 inflammasome is required in murine asthma in the absence of aluminum adjuvant. Allergy 2011; 66:1047-1057.